Loader
We have noticed an unusual activity from your IP 199.16.157.183 and blocked access to this
We have noticed an unusual activity from your IP 199.16.157.183 and blocked access to this
Daniel M. Geynisman, MD, Chief of the Division of Genitourinary Medical Oncology and an Associate Professor in the Department of Hematology/Oncology at Fox Chase Cancer…
FHD-286 reduced chromatin accessibility, repressed c-Myc and PU.1, and diminished leukemia-initiating potential in AML stem/progenitor cells.FHD-286 combin
Joaquim Bellmunt, MD, PhD, discusses the impact of enfortumab vedotin plus pembrolizumab on the treatment paradigm in first-line urothelial cancer.
Navigate the evolving paradigms in advanced ovarian cancer care. Delve into the latest treatments and methodologies improving patient outcomes.
Eliezer Van Allen, MD, discusses immuno-oncology in relation to precision cancer medicine.
The panelists provide their final thoughts, exploring the prospective treatment landscape for patients with CRC.
Key findings from COMFORT I and COMFORT II studies are examined.
The NCI SBIR Innovation Lab podcast reaches and engages with entrepreneurs of all levels to share insights on commercialization and success stories from biotech industry…
Through clinical research led by our Katy Rezvani, M.D., Ph.D., CAR NK cell therapy has now become an experimental treatment option for multiple cancers . Learn…
Join the ASTCT President, Dr. Corey Cutler, for a quarterly Town Hall to learn more about ongoing efforts within